Drugs facing NCE-1 in 2026
1. Amvuttra patent expiration
AMVUTTRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(7 years from now) | |
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(7 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(10 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(10 years from now) | |
| US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
| US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
| US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
| US12049628 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| New Indication(I-964) | Mar 20, 2028 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
2. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 months from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(1 year, 22 days from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(4 years from now) | |
| US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(4 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(4 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 months from now) | |
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 months from now) | |
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(1 year, 2 months from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US12138257 | MELINTA | Antimicrobial compositions |
May, 2032
(6 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US12036219 | MELINTA | Methods of treating infections in overweight and obese patients using antibiotics |
Jun, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...
Dosage: TABLET; POWDER
More Information on Dosage
BAXDELA family patents
3. Bludigo patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11845867 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Nov, 2036
(11 years from now) | |
| US11499050 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(12 years from now) | |
| US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 08, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 08 July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
BLUDIGO family patents
4. Bosulif patent expiration
BOSULIF's oppositions filed in EPO
BOSULIF IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(7 years ago) | |
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(1 year, 3 months ago) | |
| US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(7 years ago) | |
|
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(8 months ago) | |
| US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(4 months from now) | |
| US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(4 months from now) | |
|
US7417148 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(10 months from now) | |
|
US7919625 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(10 months from now) | |
|
US7767678 (Pediatric) | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
May, 2027
(1 year, 10 months from now) | |
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(8 years from now) | |
|
US11103497 (Pediatric) | PF PRISM CV | Treatment of imatinib resistant leukemia |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating a neoplasm; A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy; A method for treating a bcrabl positive leukemi...
Dosage: TABLET
How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage
BOSULIF family patents
5. Camzyos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50050 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(8 years from now) | |
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-297) | Jun 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2027 |
| Orphan Drug Exclusivity(ODE-398) | Apr 28, 2029 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 28 April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE
More Information on Dosage
CAMZYOS family patents
6. Cibinqo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 09, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET
More Information on Dosage
CIBINQO family patents
7. Elucirem patent expiration
ELUCIREM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(3 years from now) | |
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590246 | GUERBET | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
Jan, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
8. Epclusa patent expiration
EPCLUSA's oppositions filed in EPO
EPCLUSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(5 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(7 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(7 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(7 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| ODE*(ODE*) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 19 September, 2026
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET
More Information on Dosage
EPCLUSA family patents
9. Farxiga patent expiration
FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(4 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 2 months ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months ago) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(14 days ago) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(2 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(5 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(8 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 1 month from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 1 month from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(1 year, 7 months from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(1 year, 7 months from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(1 year, 11 months from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(2 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(2 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(2 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(2 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
|
US8221786 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US8716251 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US7851502 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Feb, 2029
(3 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(4 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(4 years from now) | |
|
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(4 years from now) | |
|
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(5 years from now) | |
|
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(5 years from now) | |
| US11826376 | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jul, 2039
(14 years from now) | |
|
US11826376 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jan, 2040
(14 years from now) | |
| US11903955 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(14 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(14 years from now) | |
|
US10973836 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) | |
|
US11903955 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) | |
| US12213988 | ASTRAZENECA AB | Methods of treating chronic kidney disease with dapagliflozin |
Apr, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-r...
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
10. Krazati patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10689377 | BRISTOL | KRas G12C inhibitors |
May, 2037
(11 years from now) | |
| US12281113 | BRISTOL | Crystalline forms of a KRas G12C inhibitor |
Sep, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
Dosage: TABLET
More Information on Dosage
KRAZATI family patents
11. Lenvima patent expiration
LENVIMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(3 months from now) | |
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(1 year, 2 months from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7253286 (Pediatric) | EISAI INC | Nitrogen-containing aromatic derivatives |
Apr, 2026
(9 months from now) | |
|
US7612208 (Pediatric) | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Mar, 2027
(1 year, 8 months from now) | |
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(2 years from now) | |
|
US9006256 (Pediatric) | EISAI INC | Antitumor agent for thyroid cancer |
Jan, 2028
(2 years from now) | |
| US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(10 years from now) | |
|
US10259791 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US11186547 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US10407393 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
| US12083112 | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Mar, 2036
(10 years from now) | |
|
US11090386 (Pediatric) | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Aug, 2036
(11 years from now) | |
|
US12083112 (Pediatric) | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Sep, 2036
(11 years from now) | |
| US12226409 | EISAI INC | Treatment of hepatocellular carcinoma |
May, 2038
(12 years from now) | |
|
US12226409 (Pediatric) | EISAI INC | Treatment of hepatocellular carcinoma |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension; Treatment of patients with pmmr/not msi-h advanced endom...
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
12. Lytgobi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(7 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET
More Information on Dosage
LYTGOBI family patents
13. Mounjaro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(10 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295987 | ELI LILLY AND CO | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Treatment of type 2 diabetes by administering in 4 doses, at least 2 weeks apart, a gip:glp-1 peptide having a gip:glp-1 receptor agonist potency ratio in a range determined by a casein camp assay, wh...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
14. Mounjaro (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(5 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(5 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| US12295987 | ELI LILLY AND CO | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Treatment of type 2 diabetes by administering in 4 doses, at least 4 weeks apart, a gip:glp-1 peptide having a gip:glp-1 receptor agonist potency ratio in a range determined by a casein camp assay, wh...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO (AUTOINJECTOR) family patents
15. Nucynta patent expiration
NUCYNTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(17 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(8 years ago) | |
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(2 years ago) | |
|
US7994364 (Pediatric) | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Dec, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Patient Population(NPP) | Jul 03, 2026 |
| Pediatric Exclusivity(PED) | Jan 03, 2027 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 03 January, 2026
Market Authorisation Date: 20 November, 2008
Treatment: Management of moderate to severe acute pain; Relief of moderate to severe acute pain
Dosage: TABLET; SOLUTION
How can I launch a generic of NUCYNTA before it's drug patent expiration?
More Information on Dosage
NUCYNTA family patents
16. Ofev patent expiration
OFEV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(1 year, 4 months ago) | |
| US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7989474 | BOEHRINGER INGELHEIM | Use of Lck inhibitors for treatment of immunologic diseases |
Apr, 2024
(1 year, 3 months ago) | |
| US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(5 months from now) | |
|
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(8 months from now) | |
|
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(11 months from now) | |
| US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(3 years from now) | |
| US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(3 years from now) | |
|
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(4 years from now) | |
|
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
17. Omlonti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648097 | OCUVEX THERAP | Pyridylaminoacetic acid compound |
Oct, 2029
(4 years from now) | |
| US10774072 | OCUVEX THERAP | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685986 | OCUVEX THERAP | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(4 years from now) | |
| USRE48183 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10702511 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11793798 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11197849 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10179127 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US9415038 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10765750 | OCUVEX THERAP | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11666563 | OCUVEX THERAP | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
18. Otezla patent expiration
OTEZLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(6 years ago) | |
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(1 year, 7 months ago) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(2 years ago) | |
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(2 years ago) | |
|
US7427638 (Pediatric) | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Aug, 2028
(3 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(8 years from now) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(8 years from now) | |
|
US9872854 (Pediatric) | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
Nov, 2034
(9 years from now) | |
|
US10092541 (Pediatric) | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-694) | Sep 23, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
| New Indication(I-884) | Dec 20, 2024 |
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
| New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of psoriatic arthrit...
Dosage: TABLET
How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage
OTEZLA family patents
19. Pluvicto patent expiration
PLUVICTO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11318121 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
| US10406240 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
| US10398791 | NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11951190 | NOVARTIS | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
Nov, 2035
(10 years from now) | |
| US12208102 | NOVARTIS | Methods of treating cancer |
Sep, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
| New Indication(I-965) | Mar 28, 2028 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor pathway inh...
Dosage: SOLUTION
More Information on Dosage
PLUVICTO family patents
20. Pomalyst patent expiration
POMALYST's oppositions filed in EPO
POMALYST IPR and PTAB Proceedings
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8828427 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5653517 | BRISTOL | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul, 2016
(8 years ago) | |
| US5635517 | BRISTOL | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul, 2016
(8 years ago) | |
| US6476052 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(8 years ago) | |
| US6316471 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Aug, 2016
(8 years ago) | |
| US8158653 | BRISTOL | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug, 2016
(8 years ago) | |
| US8204763 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
| US6561976 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
| US6908432 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
| US8589188 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
| US6045501 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
| US8626531 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(4 years ago) | |
| US6561977 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(4 years ago) | |
| US6755784 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(4 years ago) | |
| US6315720 | BRISTOL | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(4 years ago) | |
| US8315886 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(4 years ago) | |
| US8673939 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(2 years ago) | |
| US8735428 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(2 years ago) | |
|
US8673939 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 7 months ago) | |
|
US8735428 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 7 months ago) | |
| US8198262 | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(27 days ago) | |
|
US8198262 (Pediatric) | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(5 months from now) | |
| US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(4 years from now) | |
| US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(4 years from now) | |
|
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(5 years from now) | |
|
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(5 years from now) | |
|
US8828427 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
| New Indication(I-707) | Apr 23, 2018 |
| Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
| Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
| M(M-14) | Nov 20, 2023 |
| Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
| Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
| Pediatric Exclusivity(PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide while ...
Dosage: CAPSULE
How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage
POMALYST family patents
21. Pyrukynd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49582 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(5 years from now) | |
| US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(5 years from now) | |
| US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(7 years from now) | |
| US11793806 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Apr, 2033
(7 years from now) | |
| US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(13 years from now) | |
| US11878049 | AGIOS PHARMS INC | Mitapivat therapy and modulators of cytochrome P450 |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the t...
Dosage: TABLET
More Information on Dosage
PYRUKYND family patents
22. Quviviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(7 years from now) | |
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
| M(M-200) | Sep 30, 2027 |
| M(M-310) | Sep 30, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET
More Information on Dosage
QUVIVIQ family patents
23. Relyvrio patent expiration
RELYVRIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(8 years from now) | |
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(8 years from now) | |
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(8 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(8 years from now) | |
| US11583542 | AMYLYX | Compositions of bile acids and phenylbutyrate compounds |
Jul, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
| Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION
More Information on Dosage
RELYVRIO family patents
24. Rezlidhia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12275715 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
| US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
| US12053463 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
| US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
| US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
| US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(13 years from now) | |
| US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(13 years from now) | |
| US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(14 years from now) | |
| US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...
Dosage: CAPSULE
More Information on Dosage
REZLIDHIA family patents
25. Solosec patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849884 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US11324721 | EVOFEM INC | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(10 years from now) | |
| US10335390 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US10857133 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US11000507 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US11602522 | EVOFEM INC | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(10 years from now) | |
| US11020377 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US10682338 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US11000508 | EVOFEM INC | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(10 years from now) | |
| US11684607 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
| US12280037 | EVOFEM INC | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
| New Indication(I-866) | Jun 30, 2024 |
| New Patient Population(NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older
Dosage: GRANULE
More Information on Dosage
SOLOSEC family patents
26. Sotyktu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(8 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
SOTYKTU family patents
27. Sunlenca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(8 years from now) | |
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
| US11944611 | GILEAD SCIENCES INC | Capsid inhibitors for the treatment of HIV |
Aug, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: SOLUTION; TABLET
More Information on Dosage
SUNLENCA family patents
28. Terlivaz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
| Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER
More Information on Dosage
TERLIVAZ family patents
29. Trintellix patent expiration
TRINTELLIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(11 months from now) | |
| US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476279 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct, 2022
(2 years ago) | |
|
US7144884 (Pediatric) | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Dec, 2026
(1 year, 5 months from now) | |
| US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
| US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 10 months from now) | |
|
US9861630 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US9125910 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US9125909 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US9125908 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US9227946 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US8969355 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US11458134 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(2 years from now) | |
|
US8722684 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2031
(6 years from now) | |
| US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(6 years from now) | |
|
US9278096 (Pediatric) | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Sep, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, ...
Dosage: TABLET
How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage
TRINTELLIX family patents
30. Vabomere patent expiration
VABOMERE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12171772 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...
Dosage: POWDER
More Information on Dosage
VABOMERE family patents
31. Veklury patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(4 years from now) | |
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(6 years from now) | |
| US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(6 years from now) | |
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(10 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46762 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(4 years from now) | |
|
US8318682 (Pediatric) | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(4 years from now) | |
|
US8008264 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Mar, 2030
(4 years from now) | |
|
US10065958 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Mar, 2032
(6 years from now) | |
|
US11492353 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Jun, 2032
(6 years from now) | |
|
US9949994 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
|
US9724360 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
| US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
|
US10695361 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US11007208 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US11382926 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
| US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
| US11975017 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
|
US11975017 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
|
US11266681 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
|
US10675296 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(13 years from now) | |
| US11975012 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11903953 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
|
US11975012 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(16 years from now) | |
|
US11491169 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(16 years from now) | |
|
US11903953 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (birth to < 18 years of age weighing > 1.5 kg); Treatment of coronavirus disease 2019 (covid-19) in a...
Dosage: SOLUTION; POWDER
More Information on Dosage
VEKLURY family patents
32. Vonjo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8153632 | SOBI | Oxygen linked pyrimidine derivatives |
Jan, 2029
(3 years from now) | |
| US8980873 | SOBI | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9573964 | SOBI | Oxygen linked pyrimidine derivatives |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE
More Information on Dosage
VONJO family patents
33. Vtama patent expiration
VTAMA's oppositions filed in EPO
VTAMA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10647649 | ORGANON LLC | Process for preparing tapinarof |
Nov, 2038
(13 years from now) | |
| US11597692 | ORGANON LLC | Process for preparing tapinarof |
Nov, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612573 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11622945 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US10426743 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11617724 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11458108 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US10195160 | ORGANON LLC | Topical pharmaceutical compositions |
May, 2036
(10 years from now) | |
| US11938099 | ORGANON LLC | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(14 years from now) | |
| US11497718 | ORGANON LLC | Use of tapinarof for the treatment of atopic dermatitis |
Nov, 2039
(14 years from now) | |
| US11590088 | ORGANON LLC | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
| New Indication(I-956) | Dec 12, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults; Topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Dosage: CREAM
More Information on Dosage
VTAMA family patents
34. Xenoview patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583205 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Feb, 2035
(9 years from now) | |
| US11052161 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Dec, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2027 |
Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient
NCE-1 date: 23 December, 2026
Market Authorisation Date: 23 December, 2022
Treatment: NA
Dosage: GAS
More Information on Dosage
XENOVIEW family patents
35. Xigduo Xr patent expiration
XIGDUO XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(2 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(4 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(8 months from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(1 year, 11 months from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(2 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(4 years from now) | |
|
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(4 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(5 years from now) | |
|
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(5 years from now) | |
|
US9616028 (Pediatric) | ASTRAZENECA AB | Bilayer tablet formulations |
May, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage
XIGDUO XR family patents
36. Zepbound patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11918623 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND family patents
37. Zepbound (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(5 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(5 years from now) | |
| US11918623 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND (AUTOINJECTOR) family patents
38. Ztalmy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 4 months from now) | |
| US12144801 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(12 years from now) | |
| US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older; Treatment of seizures associated with cyclin-dependent kina...
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents